Joel de León

Joel de León

Auto-generated profile, based on publicly available information

Joel de León

Tumor Immunology Direction, Havana, Cuba; Center of Molecular Immunology, Havana, Cuba

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RPRolando Pérez-vela
Rolando Pérez-vela
TCTania Crombet
Tania Crombet
JLJoel de Leon
Joel de Leon
EMErnesto Moreno
Ernesto Moreno
Tumor cell growth and survival can often be impaired by inactivating a single oncogen – a phenomenon that has been called as 'oncogene addiction'. It is in such scenarios that molecular targeted therapies may succeed. Among known oncogenes, the epidermal growth factor receptor (EGFR) has become the target of different cancer therapies. So far, however, the clinical benefit from EGFR-targeted therapies has been rather limited. A critical review of the large amount of clinical data obtained with anti-EGFR agents, carried out from the perspective of the oncogene addiction concept, may help to understand the causes of the unsatisfactory results. In this article we intend to do such an exercise taking as basis for the analysis a few case studies of anti-EGFR agents that are currently in the clinic. There, the 'EGFR addiction' phenomenon becomes apparent in high-responder patients. We further discuss how the concept of oncogene addiction needs to be interpreted on the light of emerging experimental evidences and ideas; in particular, that EGFR addiction may reflect the interconnection of several cellular pathways. In this regard we set forth several hypotheses; namely, that requirement of higher glucose uptake by hypoxic tumor cells may reinforce EGFR addiction; and that chronic use of EGFR-targeted antibodies in EGFR-addicted tumors would induce stable disease by reversing the malignant phenotype of cancer stem cells and also by sustaining an anti-tumor T cell response. Finally, we discuss possible reasons for the failure of certain combinatorial therapies involving anti-EGFR agents, arguing that some of these agents might produce either a negative or a positive trans-modulation effect on other oncogenes. It becomes evident that we need operational definitions of EGFR addiction in order to determine which patient populations may benefit from treatment with anti-EGFR drugs, and to improve the design of these therapies.

29 February 2008 in International Immunology
Verified
Journal Article
Open access
PDF file
JLJoel de León
Joel de León
AFAudry Fernández
Audry Fernández
MCMarilyn Clavell
Marilyn Clavell
MLMayrel Labrada
Mayrel Labrada
YBYanin Bebelagua
Yanin Bebelagua
LFLuis E. Fernández
Luis E. Fernández
Increasing evidences suggest that the aberrant expression of certain gangliosides on malignant cells could affect host's anti-tumour-specific immune responses. We have recently documented the relevance of the N-glycolylated variant of GM3 ganglioside (NGcGM3), a tumour-specific non-human sialic acid containing ganglioside, for tumour progression. However, evidences about the implication of host's immunity in NGcGM3-promoted cancer progression had not been obtained previously. In this work, we compared tumour growth of X63 myeloma cells pre-treated or not with an inhibitor of the glucosylceramide synthase enzyme, in wild or CD4+ T cell-depleted BALB/c mice. Results clearly showed a relationship between the agonistic effect of NGcGM3 in tumour growth and the presence of CD4+ T lymphocytes. For the first time, a description of a ganglioside-differential effect over purified CD4+CD25− and naturally occurring regulatory CD4+CD25+ T cells is provided. While NGcGM3 similarly down-modulated the CD4 expression in both cell populations, the inhibitory capacity of the CD4+CD25+ lymphocytes and their proliferation, induced by an anti-CD3 mAb and IL2, were not modified. In a different fashion, a reduction in proliferative capacity and a noteworthy secretion of anti-inflammatory cytokines were detected when CD4+CD25− T cells were cultured in the presence of NGcGM3. Considering the relevance of dendritic cells (DC) on primary activation of T cells, the effect of NGcGM3 over DC differentiation and TLR4-mediated maturation was also assessed. Our results indicate that NGcGM3 contributes to cancer progression mainly by influencing DC and CD4+CD25− T lymphocyte functions, rather than increasing the inhibitory capacity of naturally occurring regulatory T cells.

1 January 2007
Verified
Book Chapter
Closed access
PDF file
MPMiroslava Potapenko
Miroslava Potapenko
GSGalina V. Shurin
Galina V. Shurin
JLJoel de León
Joel de León

1 May 2014 in Cellular Immunology
Verified
Journal Article
Closed access
NSNilda Sánchez
Nilda Sánchez
AMAlex Miranda
Alex Miranda
JFJuan M. Funes
Juan M. Funes
GHGiselle Hevia
Giselle Hevia
RPRolando Pérez
Rolando Pérez
JLJoel de León
Joel de León

30 June 2011 in Immunology Letters
Verified
Journal Article
Closed access
AMA. Miranda
A. Miranda
JLJ. de León
J. de León
LRL. Roque-Navarro
L. Roque-Navarro
LFL.E. Fernández
L.E. Fernández